Brokers bullish on SREI Infra, L&T, Alembic, Marico

Published on Tue, Dec 26, 2006 at 08:50 |  Source : Moneycontrol.com

Updated at Tue, Dec 26, 2006 at 08:53  

6837 Investors following Alembic. Share this News with them.
0
0
Share on Tumblr

Emkay has kept buy rating on SREI Infrastructure; with a target of Rs 70.

Citigroup has kept buy rating on L&T; with a target of Rs 1579.

CLSA has kept outperformer rating on Reliance Communications; with a target of Rs 486.

ICICI Securities has kept buy rating on Alembic; with a target of Rs 87.

ICICI Securities has kept buy rating on Marico and Adlabs Films.

DSP Merrill Lynch has kept buy rating on Panacea Biotech; with a target of Rs 513.

Karvy has maintained outperformer rating on ACC; with a target of Rs 1230.

Karvy has kept buy rating on Tata Steel; with a target of Rs 671.

Karvy has kept buy rating on JSW Steel; with a target of Rs 468.

House

Stocks

Views

Emkay

SREI Infrastructure

Buy; with a target of Rs 70

Citigroup

L&T

Buy; with a target of Rs 1579

CLSA

Reliance Communications

Outperformer; with a target of Rs 486

ICICI Securities

Alembic

 

 

Marico and Adlabs Films

Buy; with a target of Rs 87

 

Buy

DSP Merrill Lynch

Panacea Biotech

Buy; with a target of Rs 513

Karvy

ACC

 

 

Tata Steel

 

 

JSW Steel

Outperformer; with a target of Rs 1230

 

Buy; with a target of Rs 671

 

Buy; with a target of Rs 468

  

More on Moneycontrol

Trending News

Business News

How to Root and install Custom Recovery on any Android phone
Forget the IIP: there's free cash oozing out of every pore "Forget the IIP: there's free cash oozing out of every pore "

DLF Says Macro Environment Unfavourable W/High Comm & Labour Inflation

The latest earning numbers FIRST on CNBC-TV18
Videos

Feb 10 2012, 21:39

Tulsian buys steel stocks; negative on sugar, ADAG

- in MARKET OUTLOOK

Feb 10 2012, 21:39

Truck demand sluggish; margins down 80bps: Shriram Trans

- in Results Boardroom

Interviews

Feb 10 2012, 15:43 | Source: CNBC-TV18

Growth in margins sustainable going forward: Shasun Pharma  

Feb 10 2012, 15:35 | Source: CNBC-TV18

Expect Q4 GRMs to be similar to Q3: BPCL  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!

Follow moneycontrol.com